Cargando…
Sequential treatment with alectinib in crizotinib-resistant non-small-cell lung cancer
Autores principales: | Majumdar, Swaratika, Noronha, Vanita, Joshi, Amit, Patil, Vijay, Kumar, Rajiv, Trivedi, Vaibhavi, Prabhash, Kumar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6069325/ https://www.ncbi.nlm.nih.gov/pubmed/30112339 http://dx.doi.org/10.4103/sajc.sajc_199_18 |
Ejemplares similares
-
Osimertinib in Indian patients with T790M-positive advanced nonsmall cell lung cancer
por: Noronha, Vanita, et al.
Publicado: (2017) -
Use of lorlatinib subsequent to crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience
por: Talreja, Vikas T., et al.
Publicado: (2019) -
Lorlatinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience
por: Talreja, Vikas T., et al.
Publicado: (2020) -
An exceptional response to olaparib in relapsed and refractory BRCA2 mutated non-small cell lung cancer in hereditary breast–ovarian cancer syndrome
por: Talreja, Vikas T., et al.
Publicado: (2020) -
Crizotinib: A comprehensive review
por: Sahu, Arvind, et al.
Publicado: (2013)